[Measurement of anti-HLA antibody by lymphocytotoxicity test in patients with hematopoietic diseases].
Evaluation of anti-HLA antibody (HLA-Ab) by lymphocytotoxicity test (LCT) was reviewed in 69 patients with hematopoietic diseases. Twenty-five (36.2%) of these 69 patients developed HLA-Ab at some time during their treatment course. In patient characteristics, eleven of 32 patients with ANLL (34.4%), one of ten patients with ALL (10%), four of nine patients with CML-BC (44.4%), six of seven patients with AA (85.7%), two of four patients with MDS (50%), and one of seven patients with other types (14.3%), who had random-donor transfusion, developed HLA-Ab. Transfused leukocytes count during two months from initial transfusion were compared between LCT positive group and LCT negative group. There were no significant differences between leukocytes count (13.8 x 10(9] of LCT positive group and that (14.2 x 10(9] of LCT negative group. As the result, we can enumerate the following factors, which are important to develop HLA-Ab. The HLA phenotype and immunity of patients may have a more important role than total transfusion volume. The longterm and continuous transfusion may increase the possibility to develop HLA-Ab. The transfusion purging leukocytes may diminish the occasions of alloimmunization. HLA-matched platelet transfusions were best against the patients who developed HLA-Ab and became refractory to platelet transfusion.
Kambayashi
H
H
Ohto
H
H
Kariyone
S
S
Tanaka
T
T
D000328:Adult; D000368:Aged; D000961:Antilymphocyte Serum / Q000032:analysis*; D001803:Blood Transfusion; D003601:Cytotoxicity Tests, Immunologic; D006680:HLA Antigens / Q000276:immunology*; D006402:Hematologic Diseases / Q000276:immunology* / Q000628:therapy; D006801:Humans; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D008875:Middle Aged
D000961:Antilymphocyte Serum; D006680:HLA Antigens